Catumaxomab
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: korjuny
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Catumaxomab is a drug catalogued in DrugCentral. It was first approved by the EMA in 2025. DrugCentral lists 1 molecular target, including EPCAM. Recorded indications include Malignant ascites in adults with EpCAM-positive epithelial carcinomas.
- Molecular targets: EPCAM (1 listed in DrugCentral).
- Indications: Malignant ascites in adults with EpCAM-positive epithelial carcinomas.
- ATC code: L01FX03 (Other monoclonal antibodies and antibody drug conjugates).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Malignant ascites in adults with EpCAM-positive epithelial carcinomas
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Epithelial cell adhesion molecule | EPCAM | other | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2025-02-10 | EMA | — | Atnahs Pharma Netherlands B.V. |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FX03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Catumaxomab used for?
DrugCentral lists the following indications for Catumaxomab: Malignant ascites in adults with EpCAM-positive epithelial carcinomas.
How does Catumaxomab work?
Its molecular targets in DrugCentral include EPCAM.
When was Catumaxomab first approved?
Catumaxomab was first approved by the EMA in 2025.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5853 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2108581 — compound record and bioactivity
- DrugBank DB06607 — drug record
- FDA UNII M2HPV837HO — substance identity
- UniProt P16422 (EPCAM) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.